Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

Lancet

Volumn 349, Issue 9054, 1997, Pages 747-752

  Pitt, Bertram ^a   Segal, Robert ^g   Martinez, Felipe A ^b   Meurers, Georg ^c   Cowley, Alan J ^d   Thomas, Ignatius ^e   Deedwania, Prakash C ^f   Ney, Dawn E ^g   Snavely, Duane B ^g   Chang, Paul I ^g  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b Instituto de Medicina la Paz   (Argentina)

^c Innere Medizin Kardiologie   (Germany)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e Medical Research Institute   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN;

AGED; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TASTE DISORDER;

EID: 0030902115     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)01187-2     Document Type: Article

References (31)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
3. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
4. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10.
5. Pfeffer MA, Braunwald E, Moye LA, et al, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-77.
6. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 812-28.
7. Fonarow GC, Chelimsky-Fallick C, Warner Stevenson L, et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol 1992; 19: 842-50.
8. Gruppo Italiano per lo Studio delia Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.
9. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in over 58050 patients with suspected acute myocardial infarction. ISIS-4 (fourth International Study of Infant Survival) Collaborative Group. Lancet 1995; 345: 669-85.
10. Pitt B, Chang P, Timmermans P. Angiotensin II receptor antagonists in heart failure: rationale and design of the Evaluation of Losartan in the Elderly (ELITE) trial. Cardiovasc Drugs Ther 1995; 9: 693-700.
11. Gavras I. Bradykinin-mediated effects of ACE inhibition. Kidney Int 1992; 42: 1020-29.
12. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-42.
13. Chalmers D, Dombey SL, Lawson DH. Post-marketing surveillance of captopril (for hypertension): a preliminary report. Br J Clin Pharmacol 1987; 24: 343-49.
14. Lacourciere Y, Brunne H, Irwin R, et al, and the Losartan cough Study Group. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertension 1994; 12: 1387-93.
15. Stafford RS, Saglam D, Blumenthal D. Low rates of angiotensin-converting enzyme inhibitor use in congestive heart failure. Circulation 1996; 94: 1-194 (abstr).
16. Timmermans P, Wong PC, Chin AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-51.
17. Miura S, Ideishi M, Sakai T, et al. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertension 1994; 12: 1177-81.
18. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human chymase. J Biol Chem 1990; 265: 22348-57.
19. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertension 1994; 12: S17-S22.
20. Aldigier JC, Huang H, Dalmay F, et al. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol 1993; 21: 289-95.
21. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995; 91: 691-97.
22. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88: 1602-09.
23. Klinger G, Jaramillo N, Ikram H, et al. Effects of losartan on exercise capacity, morbidity and mortality in patients with symptomatic heart failure. J Am Coll Cardiol 1997; 29 (suppl A); 205A (abstr).
24. Packer M, Lee WH, Yushak M, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986; 315: 847-53.
25. Applefield MM. Chronic congestive heart failure: where have we been? where are we heading? Am J Med 1986; 80 (suppl 2B): 73-77.
26. Waldo AL, Cann AJ, deRuyter H, et al for the SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7-12.
27. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on the mortality and morbidity in patients with heart failure. JAMA 1995; 18: 1450-455.
28. Cohn JN. The management of chronic heart failure. N Engl J Med 1996; 335: 490-98.
29. Brasch H, Sierolawski L, Dominiak P. Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors. Hypertension 1993; 22: 699-704.
30. Minisi AJ, Thames MD. Distribution of left ventricular sympathetic afferents demonstrated by reflex responses to transmural myocardial ischemia and to intracoronary and epicardial bradykinin. Circulation 1993; 87: 240-46.
31. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20: 301-06.